Life Insurance for Cancer Survivors – Free Seminar from Dattoli Cancer Foundation
(SARASOTA, Fla., February 7, 2017) Dattoli Cancer Foundation will host a presentation by financial professionals for cancer survivors, spouses, caregivers, friends and family members. “Your Journey: New Financial and Planned Giving Opportunities” will be held on Thursday, February 23, from 6 to 7:30 p.m.
Presenters include Joseph M. Kaminski, MD, of the Dattoli Cancer Center; James W. Collins, a nationally recognized estate attorney and founding partner in Borkus Collins Law, PA; and Thomas V. Cannizzaro CFP©,CLU, ChFC, a specialist In Life Insurance-Based Financial Planning and a regular contributor to Dattoli Cancer Foundation’s Journey magazine.
The seminar will explain how individuals who have had a cancer diagnosis can still benefit from life insurance and how they can “leverage their generosity” with life insurance-based planned giving.
Panelists will provide answers to common questions, including:
• How can I, as a cancer survivor, qualify for life insurance?
• Do I need to update my life insurance planning?
• How can I be sure I will be getting the full value of my current life insurance coverage?
• What can I do to support the charitable causes my family and I care about, without a substantial financial burden?
This is an informal, no-cost program that will be held in Dattoli Cancer Center’s Education Center on the second floor at 2803 Fruitville Rd., Sarasota. Registration is requested. Reservations can be made by phone: (941) 365-5599. RSVP deadline is February 20.
About the Dattoli Cancer Foundation:
The Dattoli Cancer Foundation is a not-for-profit (501) (c) (3) organization that provides prostate cancer information, support, free screenings and literature that will assist prostate cancer patients, their families and supporters. The Foundation increases awareness about the importance of PSA screening; offers current, accurate information about leading-edge treatment; and fosters research leading to improved treatment options for prostate cancer.
# # #